All sponsors

Boehringer Ingelheim

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS48
PHASE 3 / 2-328
RECRUITING29
READOUTS ≤12 MONTHS16
READOUT SLIPPED >6 MO28%

Delay Index: of 25 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Boehringer Ingelheim on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
zongertinib
NCT06151574
P3Active, not recruitingLung Cancer, Non-squamous, Non-small Cell4282026-12-10 (-4 mo)
BI 1584862
NCT06769048
P2Active, not recruitingGeographic Atrophy1502026-12-22
BI 690517
NCT06531824
P3Active, not recruitingKidney Disease, Chronic83712026-12-31 (-20 mo)
BI 764524
NCT06321302
P2RecruitingDiabetic Retinopathy1752027-03-05 (+8 mo)
BI 765423
NCT07036523
P2Active, not recruitingIdiopathic Pulmonary Fibrosis812027-03-11
Low dose BI 3812465
NCT07553429
P1/2RecruitingDiabetic Macular Edema492027-03-23
BI 1291583
NCT05846230
P2Active, not recruitingBronchiectasis2682027-03-31 (+13 mo)
Nerandomilast
NCT06806592
P3Active, not recruitingInterstitial Lung Diseases; Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases4142027-04-15
Empagliflozin
NCT07107945
P3Active, not recruitingChronic Kidney Disease1352027-04-16 (-14 mo)
FIBRONEER™-ON
NCT06238622
P3Active, not recruitingIdiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis16662027-04-28
BI 1291583
NCT06872892
P3RecruitingBronchiectasis17552027-06-15 (-15 mo)
BI 3034701
NCT07662122
P2Active, not recruitingObesity; Overweight3452027-06-26
BI 3032950 intravenous (Part A)
NCT06636656
P2RecruitingUlcerative Colitis802027-07-30 (+15 mo)
BI 3802876
NCT07325526
P2RecruitingLiver Cirrhosis302027-08-05
Zongertinib
NCT07486817
P2RecruitingLung Cancer, Non-squamous, Non-small Cell602027-08-12
TENACITY
NCT07361302
P3RecruitingAcute Ischemic Stroke13252027-10-02
BI 764532, dose 1
NCT05882058
P2RecruitingSmall Cell Lung Carcinoma; Neuroendocrine Neoplasms2042027-12-17 (+39 mo)
Survodutide
NCT07754461
P3RecruitingType 2 Diabetes6002028-01-17
BI 764198
NCT07355296
P2RecruitingProteinuric Kidney Diseases1322028-01-20
BI 3810477
NCT07926321
P2Not yet recruitingIdiopathic Pulmonary Fibrosis702028-01-27
BI 1815368
NCT06962839
P2RecruitingMacular Edema3002028-03-01 (+6 mo)
vicadrostat
NCT06424288
P3RecruitingHeart Failure67122028-05-22 (+6 mo)
Obrixtamig
NCT07929051
P3Not yet recruitingAdvanced Cancer682028-07-03
Survodutide
NCT07850050
P3Not yet recruitingObesity6002028-07-26
obrixtamig
NCT07472517
P3RecruitingSmall Cell Lung Cancer (SCLC); Extensive-stage Small Cell Lung Cancer (ES-SCLC)6702028-09-09
Zongertinib
NCT06581432
P2RecruitingSolid Tumours5882028-11-30 (+15 mo)
Nerandomilast
NCT07540988
P3RecruitingInterstitial Lung Diseases4662028-12-05
BI 764198
NCT07220083
P3RecruitingFocal Segmental Glomerulosclerosis2862028-12-27 (-14 mo)
Zongertinib
NCT06324357
P1/2RecruitingMetastatic Breast Cancer; Metastatic Gastric Adenocarcinoma9102029-01-08 (+23 mo)
vicadrostat
NCT06935370
P3RecruitingHeart Failure42002029-02-04
BI 3000202
NCT07409181
P2RecruitingSystemic Lupus Erythematosus4052029-02-04
Nerandomilast
NCT07366034
P3RecruitingFibrosing Interstitial Lung Disease352029-04-27
Survodutide
NCT07850063
P3Not yet recruitingObesity; Metabolic Dysfunction-associated Steatotic Liver Disease6002029-04-29
Nerandomilast
NCT07201922
P3RecruitingFamilial Pulmonary Fibrosis; Interstitial Lung Abnormalities802029-05-14
Survodutide
NCT06632457
P3RecruitingMetabolic Dysfunction Associated Steatohepatitis15902029-06-05
verducatib
NCT07915219
P3Not yet recruitingBronchiectasis15002029-07-31
Survodutide
NCT07855900
P3Not yet recruitingObesity3502029-11-06
Verducatib
NCT07907991
P3Not yet recruitingChronic Obstructive Pulmonary Disease18002029-11-12
Obrixtamig
NCT07544654
P3RecruitingExtrapulmonary Neuroendocrine Cancer (epNEC)3902029-12-13
Vicadrostat
NCT07064473
P3RecruitingDiabetes Mellitus, Type 2; Hypertension118002029-12-14
VERANDA™-SSc
NCT07497087
P3RecruitingSystemic Sclerosis4482030-02-26
VERANDA™-IIM
NCT07789015
P3Not yet recruitingIdiopathic Inflammatory Myopathies2702030-03-21
Obrixtamig
NCT07843940
P1/2RecruitingExtensive-stage Small Cell Lung Carcinoma; Advanced Small Cell Lung Cancer552030-04-17
Obrixtamig
NCT07707895
P1/2RecruitingSmall Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma602030-04-26
Brigimadlin
NCT06619509
P2Active, not recruitingSolid Tumours902030-12-30 (-72 mo)
Survodutide
NCT06632444
P3RecruitingMetabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis18002031-12-27
Zongertinib
NCT07195695
P3RecruitingNon-small Cell Lung Cancer4002032-02-26
BI 3720931
NCT06962852
P1/2Active, not recruitingCystic Fibrosis52040-10-29 (-83 mo)